Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjogren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.

ABSTRACT: Resolvin D1 (RvD1) and its aspirin-triggered epimeric form (AT-RvD1) are endogenous lipid mediators (derived from docosahexaenoic acid, DHA) that control the duration and magnitude of inflammation in models of complex diseases. Our previous studies demonstrated that RvD1-mediated signaling pathways are expressed and active in salivary glands from rodents and humans. Furthermore, treatment of salivary cells with RvD1 blocked TNF-α-mediated inflammatory signals and improved epithelial integrity. The purpose of this pilot study was to determine the feasibility of treatment with AT-RvD1 versus dexamethasone (DEX) on inflammation (i.e., lymphocytic infiltration, cytokine expression and apoptosis) observed in submandibular glands (SMG) from the NOD/ShiLtJ Sjögren's syndrome (SS) mouse model befo

SUBMITTER: Easley JT 

PROVIDER: S-EPMC4841619 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature